Q2 EPS Estimates for iBio Cut by Brookline Capital Markets

Posted by on Sep 2nd, 2026

iBio, Inc. (NASDAQ:IBIO – Free Report) – Equities research analysts at Brookline Capital Markets decreased their Q2 2027 earnings per share (EPS) estimates for iBio in a note issued to investors on Sunday, August 30th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for iBio’s current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for iBio’s Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.31) EPS.

iBio (NASDAQ:IBIO – Get Free Report) last posted its quarterly earnings data on Friday, August 28th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03.

IBIO has been the subject of several other research reports. B. Riley Financial assumed coverage on shares of iBio in a research report on Friday, June 5th. They set a “buy” rating and a $6.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a research report on Wednesday, June 24th. Chardan Capital restated a “buy” rating and set a $5.00 target price on shares of iBio in a research report on Thursday, July 2nd. Raymond James Financial assumed coverage on shares of iBio in a report on Monday, June 8th. They set an “outperform” rating and a $5.00 target price for the company. Finally, Wall Street Zen downgraded shares of iBio from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Three investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, iBio presently has an average rating of “Buy” and a consensus price target of $5.00.

Read Our Latest Stock Analysis on iBio

iBio Stock Performance

Shares of NASDAQ:IBIO opened at $1.26 on Wednesday. The stock’s 50-day simple moving average is $1.47 and its two-hundred day simple moving average is $1.82. The stock has a market capitalization of $62.60 million, a price-to-earnings ratio of -3.71 and a beta of 1.29. iBio has a 52-week low of $0.77 and a 52-week high of $3.82.

Institutional Trading of iBio

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP bought a new position in shares of iBio in the third quarter worth about $37,000. XTX Topco Ltd bought a new position in shares of iBio during the 4th quarter valued at approximately $71,000. Persistent Asset Partners Ltd bought a new position in shares of iBio during the 4th quarter valued at approximately $76,000. Headlands Technologies LLC grew its stake in shares of iBio by 333.0% during the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after acquiring an additional 36,463 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in iBio in the 3rd quarter worth approximately $109,000. Hedge funds and other institutional investors own 7.90% of the company’s stock.

About iBio

(Get Free Report)

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

Featured Articles

Earnings History and Estimates for iBio (NASDAQ:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.